Patents by Inventor YONGBAO WANG

YONGBAO WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230193358
    Abstract: The present invention provides methods and compositions for determining prognosis in individual with cancer, in particular endometrial cancer. The present invention also provides methods of developing and using predictive models that are useful for determining prognosis of endometrial cancer and other similar diseases. The present invention further provides methods for determining microsatellite status using next generation sequencing.
    Type: Application
    Filed: February 21, 2023
    Publication date: June 22, 2023
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Yongbao WANG, Kevin J. ARVAI, Daniel JONES
  • Publication number: 20220364180
    Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
    Type: Application
    Filed: February 4, 2022
    Publication date: November 17, 2022
    Applicant: QUEST DIAGNOSTICS INVESTMENTS LLC
    Inventors: Yongbao Wang, Daniel Jones
  • Patent number: 11118232
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 14, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Publication number: 20200165688
    Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 28, 2020
    Applicant: QUEST DIAGNOSTICS INVESTMENT LLC
    Inventors: Yongbao Wang, Daniel Jones
  • Patent number: 10519509
    Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 31, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yongbao Wang, Daniel Jones
  • Publication number: 20190177801
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 13, 2019
    Applicant: QUEST DIAGNOSTICS INVESTMENTS LLC
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Patent number: 10155994
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 18, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Publication number: 20180094301
    Abstract: The present invention provides methods and compositions for determining prognosis in individual with cancer, in particular endometrial cancer. The present invention also provides methods of developing and using predictive models that are useful for determining prognosis of endometrial cancer and other similar diseases. The present invention further provides methods for determining microsatellite status using next generation sequencing.
    Type: Application
    Filed: February 5, 2016
    Publication date: April 5, 2018
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Yongbao WANG, Kevin J. ARVAI, Daniel JONES
  • Publication number: 20170260591
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 14, 2017
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Patent number: 9617579
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: April 11, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Publication number: 20160312303
    Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Yongbao Wang, Daniel Jones
  • Publication number: 20140220032
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: December 26, 2013
    Publication date: August 7, 2014
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: DANIEL M. JONES, YONGBAO WANG, SHERE BILLOUIN-FRAZIER, JUSTIN WINDHAM